Memery Crystal advise life sciences focused Intuitive Investments Group on its admission to AIM

Intuitive Investment Group in a newly established investing company. The net proceeds of the placing will be used to invest in fast growing and/or high potential life sciences businesses, based predominately in the UK, wider Europe and the US, chosen from an identified pipeline of investment opportunities. Investments will be focused on diagnostics and healthcare, medical devices, tools and technologies and bio-therapeutics and pharmaceuticals.

Intuitive Investment Group Chairman, David Evans, has over 27 years of experience in the Life Science sector both in private companies and as a senior director of a number of public companies. David has facilitated 12 companies’ transition to being publicly traded (directly or indirectly), has overseen four successful exits and has extensive experience chairing numerous UK public companies’ boards. He has been actively engaged in a number of M&A transactions and has a record of high returns from personal investments in the Life Science sector.

The Memery Crystal team was led by CEO Nick Davis alongside Director Melanie Talbot and Solicitor Amrit Duhra.

Nick Davis commented:

“It was a pleasure to work with David Evans and the Intuitive Investment Group team. 2020 has been a year like no other for the healthcare industry, so it is fantastic to have Intuitive Investment Group bring their experience and track record in the sector to the London Markets.

It has become increasingly necessary for healthcare companies to access sources of funding and broaden investor bases to keep up with the rapid pace of growth. We look forward to seeing Intuitive Investment Groups portfolio develop.”

Melanie Talbot commented:

“It was a pleasure to work with new client Intuitive Investment Group on its admission to AIM. What a great team to work with, I look forward to assisting them in building their portfolio of investments.”